First there was Botox, then came Dysport, and come this spring there will be a third option: Xeomin (incobotulinumtoxinA). The Food and Drug Administration (FDA) approved Xeomin in July 2011 for the treatment of severe frown lines or “11’s” between the eyes. Xeomin was already FDA approved for use in adults with cervical dystonia and blepharospasm.
While it’s still unknown how Xeomin will compare to Botox and Dysport, we do know that Xeomin is formulated differently without any additives possibly making it less likely to cause adverse reactions. Xeomin is also the only FDA-approved botulinum toxin that does not require refrigeration.
You’ll have to wait a few more months for Xeomin to be available. As soon as more information is available we’ll be sure to let you know.